In 2018, the Foundation for the National Institutes of Health (FNIH) will present the FNIH Trailblazer Prize for Clinician-Scientists (Trailblazer Prize), which recognizes the outstanding contributions of early career clinician-scientists whose work has the potential to or has led to innovations in patient care. This $10,000 honorarium and prize celebrates the achievements of medical doctors…

How to Attract Medical Students & Rheumatology Candidates
As the shortage of rheumatologists is expected to worsen, practices and fellowship programs are asking how to attract top talent. Here are tips for how individuals can raise rheumatology’s profile and reach out to med students and new rheumatologists…

Periodontitis May Provide Insight into RA
Researchers explored the role of carbamylated protein (CarP) and neutrophil extracellular traps (NETs) in periodontitis and rheumatoid arthritis (RA). The results showed significantly higher levels of CarP and NETs in patients with both RA and periodontitis than in healthy controls. The data suggest that RA and periodontitis may share an underlying pathogenic mechanism…
Priority List Could Help Produce Better Pediatric EHRs
NEW YORK (Reuters Health)—Children’s electronic health records (EHRs) are missing functions “essential” for managing children’s health, according to a multistakeholder work group that produced a “high-priority” list of EHR requirements. “Most doctors caring for children in hospitals or office practices now use EHRs, which benefit children and families by offering decision-support and other safety features…
Health Insurer Cigna to Buy Express Scripts for about $54 Billion
(Reuters)— U.S. health insurer Cigna Corp said on Thursday it would buy pharmacy benefits manager Express Scripts Holding Co for about $54 billion, a tie-up that reflects pressure on healthcare companies to grow bigger to cut costs. The move follows the $69-billion merger of insurer Aetna Inc and one of Express Scripts’ biggest rivals, CVS…
FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
WASHINGTON (Reuters)—U.S. Food and Drug Administration chief, Scott Gottlieb, criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for “Kabuki drug-pricing constructs” that profit the industry at the expense of consumers. The comments, made at a conference organized by a leading U.S. health insurer lobbying group, stoked speculation over what steps the administration of…
Novartis, U.S. Partner Plan Remote Trials to Boost Participation
ZURICH (Reuters)—Novartis plans up to 10 clinical trials over three years using a U.S. partner’s mobile technology to help free patients from burdensome hospital trips as the Swiss drugmaker aims to boost study participation and cut costs. Novartis said on Wednesday it would work with Science 37, a California-based company that provides technology including smart…

Back to the Future: Spotlight on ACR Past President Dr. Herbert Kaplan
We are sad to report that Dr. Kaplan passed away on Saturday, June 23. We are reposting this story now to celebrate his life.
Opioids No Better Than NSAIDs for Chronic Back or Arthritis Pain
(Reuters Health)—Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests. And opioids are no better than these other drugs at reducing how much pain interferes with daily activities, such as walking, working, sleeping or enjoying…

FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval
After reviewing a 10-year study, the FDA cautions that prescribing clarithromycin to patients with heart disease increases the risk of heart problems or death…
- « Previous Page
- 1
- …
- 352
- 353
- 354
- 355
- 356
- …
- 814
- Next Page »